Literature DB >> 7516493

Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae.

D C Kaslow1, G Hui, S Kumar.   

Abstract

Four antigenic variants of the 19-kDa carboxy terminal fragment of Plasmodium falciparum merozoite surface protein, MSP1 (MSP1(19)), were expressed in Saccharomyces cerevisiae as a histidine-tagged, secreted polypeptides (rMSP1(19)s). Structural analysis of the rMSP1(19)s indicated that a single amino acid change (E to Q) in the first EGF-like domain of the yeast-secreted rMSP1(19) proteins caused a significant change in their disulfide bond-dependent conformation. The antigenicity of the rMSP1(19)s were qualitatively and quantitatively analyzed by direct and competitive binding ELISAs. The data indicate that conserved and variant B cell determinants of MSP1(19), as well as epitopes that are known targets of protective antibodies, were recreated authentically in the rMSP1(19)s. Secretion of histidine-tagged rMSP1(19)s using the expression system described may be an efficient and effective means of producing a properly folded immunogen for a human vaccine against the blood stages of P. falciparum.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516493     DOI: 10.1016/0166-6851(94)90064-7

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  40 in total

1.  In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.

Authors:  Alan L Y Pang; Caryn N Hashimoto; Leslie Q Tam; Z Q Meng; George S N Hui; Walter K K Ho
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Factors associated with immunoglobulin G subclass polarization in naturally acquired antibodies to Plasmodium falciparum merozoite surface proteins: a cross-sectional survey in Brazilian Amazonia.

Authors:  Kézia K G Scopel; Cor J F Fontes; Marcelo U Ferreira; Erika M Braga
Journal:  Clin Vaccine Immunol       Date:  2006-07

3.  Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.

Authors:  Mark Nagata; Teri Wong; David Clements; George Hui
Journal:  Exp Parasitol       Date:  2006-11-21       Impact factor: 2.011

4.  Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-07-19       Impact factor: 3.641

5.  The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

6.  Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

Authors:  Matthew B McCarra; George Ayodo; Peter O Sumba; James W Kazura; Ann M Moormann; David L Narum; Chandy C John
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

7.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

8.  Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission.

Authors:  Gregory S Noland; Brett Hendel-Paterson; Xinan M Min; Ann M Moormann; John M Vulule; David L Narum; David E Lanar; James W Kazura; Chandy C John
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

9.  Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.

Authors:  T Tsuboi; D C Kaslow; M M Gozar; M Tachibana; Y M Cao; M Torii
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

10.  Erythrocytic stage-dependent regulation of oligomerization of Plasmodium ribosomal protein P2.

Authors:  Sudipta Das; Rajagopal Sudarsan; Subramanian Sivakami; Shobhona Sharma
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.